Treatment Response Evaluation of Cardiac Amyloidosis Using Serial T1- and T2-Mapping Cardiovascular Magnetic Resonance Imaging
Open Access
- 30 December 2020
- journal article
- Published by The Korean Society of Radiology in Journal of the Korean Society of Radiology
- Vol. 82 (2), 429-434
- https://doi.org/10.3348/jksr.2020.0048
Abstract
Amyloidosis is a multisystemic disease characterized by the accumulation of abnormal proteins in extracellular spaces in various organs, with frequent involvement of the myocardium. We report a case of a patient who had cardiac amyloidosis with a trend of reduction in native T1 and T2 values and extracellular volume fraction on serial cardiac magnetic resonance imaging after chemotherapy and stem cell transplantation. The native T1 value and the extracellular volume fraction are closely associated with tissue amyloid burden in amyloidosis patients. This case demonstrated that cardiac magnetic resonance imaging may be used as a non-invasive and quantitative biomarker in the treatment monitoring of amyloidosis.Keywords
This publication has 10 references indexed in Scilit:
- Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosisJournal of Cardiovascular Magnetic Resonance, 2018
- Serial Native T1 Mapping to Monitor Cardiac Response to Treatment in Light-Chain AmyloidosisCirculation: Cardiovascular Imaging, 2016
- Cardiac Amyloid LoadJournal of Invasive Cardiology, 2016
- Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center studyClinical Research in Cardiology, 2015
- T1 mapping and survival in systemic light-chain amyloidosisEuropean Heart Journal, 2014
- Noncontrast T1 Mapping for the Diagnosis of Cardiac AmyloidosisJACC: Cardiovascular Imaging, 2013
- T1 Mapping Shows Increased Extracellular Matrix Size in the Myocardium Due to Amyloid DepositionsCirculation: Cardiovascular Imaging, 2012
- Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain MeasurementsJournal of Clinical Oncology, 2012
- Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic AmyloidosisJournal of Clinical Oncology, 2004
- The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvementQJM: An International Journal of Medicine, 1998